JP2011509093A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011509093A5 JP2011509093A5 JP2010542283A JP2010542283A JP2011509093A5 JP 2011509093 A5 JP2011509093 A5 JP 2011509093A5 JP 2010542283 A JP2010542283 A JP 2010542283A JP 2010542283 A JP2010542283 A JP 2010542283A JP 2011509093 A5 JP2011509093 A5 JP 2011509093A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid residue
- peptide
- acid residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000539 amino acid group Chemical group 0.000 claims 65
- 108090000765 processed proteins & peptides Proteins 0.000 claims 35
- 239000003446 ligand Substances 0.000 claims 15
- 102000040430 polynucleotide Human genes 0.000 claims 15
- 108091033319 polynucleotide Proteins 0.000 claims 15
- 239000002157 polynucleotide Substances 0.000 claims 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims 12
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims 12
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 7
- 235000004279 alanine Nutrition 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 4
- 235000013922 glutamic acid Nutrition 0.000 claims 4
- 239000004220 glutamic acid Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 3
- 239000004473 Threonine Substances 0.000 claims 3
- 235000009582 asparagine Nutrition 0.000 claims 3
- 229960001230 asparagine Drugs 0.000 claims 3
- 230000004807 localization Effects 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 102000040945 Transcription factor Human genes 0.000 claims 2
- 108091023040 Transcription factor Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 210000005003 heart tissue Anatomy 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2013708P | 2008-01-09 | 2008-01-09 | |
| US8064008P | 2008-07-14 | 2008-07-14 | |
| PCT/US2009/000155 WO2009089059A2 (en) | 2008-01-09 | 2009-01-09 | Therapeutic inhibitors of pai-1 function methods of their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012008069A Division JP2012135307A (ja) | 2008-01-09 | 2012-01-18 | Ｐａｉ−１機能の治療的阻害因子およびその使用法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011509093A JP2011509093A (ja) | 2011-03-24 |
| JP2011509093A5 true JP2011509093A5 (enExample) | 2012-03-01 |
Family
ID=40853701
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010542283A Withdrawn JP2011509093A (ja) | 2008-01-09 | 2009-01-09 | Ｐａｉ−１機能の治療的阻害因子およびその使用法 |
| JP2012008069A Withdrawn JP2012135307A (ja) | 2008-01-09 | 2012-01-18 | Ｐａｉ−１機能の治療的阻害因子およびその使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012008069A Withdrawn JP2012135307A (ja) | 2008-01-09 | 2012-01-18 | Ｐａｉ−１機能の治療的阻害因子およびその使用法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8431363B2 (enExample) |
| EP (1) | EP2242501A4 (enExample) |
| JP (2) | JP2011509093A (enExample) |
| KR (1) | KR101712208B1 (enExample) |
| CN (1) | CN102123721A (enExample) |
| AU (1) | AU2009204464B2 (enExample) |
| BR (1) | BRPI0906867A2 (enExample) |
| CA (1) | CA2711878A1 (enExample) |
| IL (1) | IL206891A0 (enExample) |
| MX (1) | MX2010007586A (enExample) |
| RU (1) | RU2010133847A (enExample) |
| WO (1) | WO2009089059A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0906867A2 (pt) | 2008-01-09 | 2019-09-24 | Intrexon Corp | inibidores terapêuticos da função pai-1 e métodos de uso dos mesmo |
| NZ603482A (en) * | 2010-05-12 | 2014-11-28 | Tengion Inc | Bioactive renal cells |
| WO2013164970A1 (ja) * | 2012-05-01 | 2013-11-07 | 富士フイルム株式会社 | 多能性幹細胞の培養方法及びこれに用いるポリペプチド |
| CN103421781B (zh) * | 2012-07-04 | 2014-12-31 | 华中农业大学 | 猪肌肉组织特异性表达基因myf6启动子及应用 |
| EP3080156A1 (en) * | 2013-12-10 | 2016-10-19 | F. Hoffmann-La Roche AG | Use of the binding domain of a subunit of a multi-subunit structure for targeted delivery of pharmaceutically active entities to the multi-subunit structure |
| CN110167583A (zh) * | 2016-12-15 | 2019-08-23 | 泰伦基国际有限公司 | 一种治疗冠状动脉粥样硬化及其并发症的方法 |
| CN110114081A (zh) | 2016-12-15 | 2019-08-09 | 泰伦基国际有限公司 | 一种改善心脏病变的方法 |
| JP7168990B2 (ja) | 2016-12-15 | 2022-11-10 | タレンゲン インターナショナル リミテッド | 肥満症を予防および治療するための方法および薬物 |
| US11613744B2 (en) | 2018-12-28 | 2023-03-28 | Vertex Pharmaceuticals Incorporated | Modified urokinase-type plasminogen activator polypeptides and methods of use |
| EP3902913A1 (en) | 2018-12-28 | 2021-11-03 | Catalyst Biosciences, Inc. | Modified urokinase-type plasminogen activator polypeptides and methods of use |
| CN119656313A (zh) * | 2024-12-13 | 2025-03-21 | 四川大学华西医院 | Serpine1基因作为靶点在制备预防或治疗心肌纤维化药物中的用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5639726A (en) * | 1994-09-30 | 1997-06-17 | The Regents Of The University Of Michigan | Peptide mediated enhancement of thrombolysis methods and compositions |
| WO2001024815A1 (en) | 1999-10-07 | 2001-04-12 | Human Genome Sciences, Inc. | Plasminogen-like polynucleotides, polypeptides, and antibodies |
| DE10053251A1 (de) * | 2000-10-26 | 2002-05-08 | Boehringer Ingelheim Pharma | Epitope von PAI-1 |
| US20030211095A1 (en) * | 2002-05-08 | 2003-11-13 | Abd. Al-Roof Higazi | Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy |
| US20030199463A1 (en) * | 2002-04-23 | 2003-10-23 | Silviu Itescu | DNA enzyme to inhibit plasminogen activator inhibitor-1 |
| CN1668312A (zh) * | 2002-05-13 | 2005-09-14 | 洛杉矶儿童医院 | 疤痕疙瘩和其它的皮肤或内部的创伤或损伤中异常疤痕形成的处理和抑制 |
| US7241613B1 (en) | 2002-06-05 | 2007-07-10 | Oscient Pharmaceuticals Corporation | Identification of Candida cell surface proteins and their uses |
| US7785871B2 (en) | 2002-10-09 | 2010-08-31 | Intrexon Corporation | DNA cloning vector plasmids and methods for their use |
| US20080050808A1 (en) | 2002-10-09 | 2008-02-28 | Reed Thomas D | DNA modular cloning vector plasmids and methods for their use |
| US7071295B2 (en) | 2002-12-02 | 2006-07-04 | Intrexon Corporation | Signal for targeting molecules to the sarco(endo)plasmic reticulum |
| BR0316584A (pt) | 2002-12-10 | 2005-10-04 | Wyeth Corp | Derivados de ácido acético indol oxo-acetil amino substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1) |
| ES2603062T3 (es) | 2004-05-18 | 2017-02-23 | Intrexon Corporation | Métodos de ensamblaje dinámico de vectores para la clonación de ADN de vectores plasmídicos |
| US8153598B2 (en) | 2005-10-19 | 2012-04-10 | Intrexon Corporation | PKD ligands and polynucleotides encoding PKD ligands |
| WO2007048103A2 (en) | 2006-10-18 | 2007-04-26 | Intrexon Corporation | Pkd ligands and polynucleotides encoding pkd ligands |
| US7943732B2 (en) | 2006-06-05 | 2011-05-17 | Intrexon Corporation | AKT ligands and polynucleotides encoding AKT ligands |
| US8993263B2 (en) | 2006-08-07 | 2015-03-31 | Intrexon Corporation | PKA ligands and polynucleotides encoding PKA ligands |
| US8999666B2 (en) | 2006-08-09 | 2015-04-07 | Intrexon Corporation | PKC ligands and polynucleotides encoding PKC ligands |
| US8729225B2 (en) | 2006-11-13 | 2014-05-20 | Intrexon Corporation | Glycogen synthase kinase heteropolyligand polypeptide |
| US8283445B2 (en) | 2006-11-13 | 2012-10-09 | Intrexon Corporation | Extracellular-signal-regulated-kinase (ERK) heteropolyligand polypeptide |
| US7705122B2 (en) | 2006-12-04 | 2010-04-27 | Intrexon Corporation | mTOR ligands and polynucleotides encoding mTOR ligands |
| CA2680837C (en) | 2007-03-27 | 2017-06-06 | Intrexon Corporation | Mek ligands and polynucleotides encoding mek ligands |
| EP2150273A4 (en) * | 2007-04-27 | 2010-11-17 | Univ Toledo | MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR MOLECULE AND METHODS OF USE |
| BRPI0906867A2 (pt) | 2008-01-09 | 2019-09-24 | Intrexon Corp | inibidores terapêuticos da função pai-1 e métodos de uso dos mesmo |
-
2009
- 2009-01-09 BR BRPI0906867A patent/BRPI0906867A2/pt not_active IP Right Cessation
- 2009-01-09 US US12/812,127 patent/US8431363B2/en not_active Expired - Fee Related
- 2009-01-09 MX MX2010007586A patent/MX2010007586A/es active IP Right Grant
- 2009-01-09 CA CA2711878A patent/CA2711878A1/en not_active Abandoned
- 2009-01-09 EP EP09700772A patent/EP2242501A4/en not_active Withdrawn
- 2009-01-09 CN CN2009801088638A patent/CN102123721A/zh active Pending
- 2009-01-09 JP JP2010542283A patent/JP2011509093A/ja not_active Withdrawn
- 2009-01-09 AU AU2009204464A patent/AU2009204464B2/en not_active Ceased
- 2009-01-09 WO PCT/US2009/000155 patent/WO2009089059A2/en not_active Ceased
- 2009-01-09 RU RU2010133847/10A patent/RU2010133847A/ru not_active Application Discontinuation
- 2009-01-09 KR KR1020107017701A patent/KR101712208B1/ko not_active Expired - Fee Related
-
2010
- 2010-07-08 IL IL206891A patent/IL206891A0/en unknown
-
2012
- 2012-01-18 JP JP2012008069A patent/JP2012135307A/ja not_active Withdrawn
-
2013
- 2013-02-15 US US13/769,144 patent/US8828686B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011509093A5 (enExample) | ||
| US8067545B2 (en) | Isolated antibodies against biologically active leptin-related peptides | |
| Osugi et al. | Evolutionary origin of the structure and function of gonadotropin-inhibitory hormone: insights from lampreys | |
| JP2004267216A5 (enExample) | ||
| JP5547719B2 (ja) | Ｊｎｋシグナル伝達経路の細胞透過性のペプチド性阻害剤の、慢性または非慢性の炎症性消化器疾患の治療のための、使用 | |
| WO2010135491A3 (en) | Fibroblast growth factor mutants having improved functional half-life and methods of their use | |
| CN102256999A (zh) | 向白细胞的有效转运 | |
| CN104271147A (zh) | 细胞穿膜肽 | |
| TW200536859A (en) | Gastrointestinal proliferative factor and uses thereof | |
| JP2011501652A5 (enExample) | ||
| EP2589658A4 (en) | PARTIAL REGION POLYPEPTIDE OF REIC / DKK-3 PROTEIN | |
| CN108473546A (zh) | Mg53突变体及其制备方法和用途 | |
| US20210340211A1 (en) | Gip peptide analogues | |
| JP2003530124A5 (enExample) | ||
| JP2020513810A5 (enExample) | ||
| KR20120059520A (ko) | 이상지질혈증을 치료하기 위한 멜라노코르틴의 용도 | |
| JP2017532013A (ja) | 寿命に関する動物モデル並びに寿命を延ばす及び腫瘍化を阻害する関連方法 | |
| JP2013523084A5 (enExample) | ||
| RU2011150283A (ru) | Пептиды ттк и вакцины, их содержащие | |
| JP2007504840A5 (enExample) | ||
| JP2005512509A5 (enExample) | ||
| CN109862903B (zh) | 治疗性sall4肽 | |
| JP2008545396A5 (enExample) | ||
| RU2013115434A (ru) | Пептиды ttll4 и содержащие их вакцины | |
| CA2460468A1 (en) | Novel polypeptide, dna thereof and use of the same |